LI-COR and NMI TT Pharmaservices have partnered to bring you DigiWest® Protein Profiling, a high-content, multiplex immunoassay performed as a contract research service. The assay allows for the quick and efficient discovery of biomarkers or characterization of potential targeted therapeutics. A DigiWest® assay provides comprehensive biological information deep into one or several cell signaling pathways.
The information gained from a DigiWest® Protein Profiling assay can help determine which targets or pathways offer the most therapeutic promise. The service can also be used to make predictions about the safety and toxicity of a therapeutic based upon functional effects and performance.
Watch to see how DigiWest® is making an impact in biomedical decision making and patient care.
Only 20 to 60 μg of total protein are required to perform a DigiWest® assay. Using just 30 μg of snap-frozen tissue or dry-frozen cells, comprehensive analyses can be done using up to 800 different antibodies. A library of over 1,200 prevalidated antibodies and over 50 predefined pathways are available for human, mouse, rat, dog, minipig, and cynomolgus samples.
A DigiWest® immunoassay can provide data on several parameters useful in the development of targeted therapeutics.
This study used DigiWest® for analysis of mechanisms and biomarkers of platinum resistance in ovarian cancer patients.
A set of 24 fresh frozen tumor specimens from relapsed vs cured platinum-treated ovarian cancer patients was analyzed by DigiWest®, using 466 antibodies (total and phospho proteins) covering various cell signaling pathways.
DigiWest® protein signatures distinguished platinum resistant vs sensitive patients, and revealed 8 promising biomarker candidates.
In this study, DigiWest® was used to perform a mode-of-action study of compounds in comparison to reference therapeutics.
Calu1 cells were treated with 1 MEK inhibitor vs 1 PI3K inhibitor vs 2 experimental lead compounds (data not shown) vs DMSO. Cell samples were analyzed by DigiWest®, using 156 selected antibodies (total and phospho proteins) covering different signal transduction pathways.
DigiWest® yielded distinct signatures for each compound and allowed for in-depth characterization of lead compounds as compared to reference therapeutic.
The analyses from a DigiWest® Protein Profiling assay provide a more complete understanding of how a therapeutic may affect a target and creates a potential new starting point in the therapeutic development process.1